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Abstract
Background. We assessed whether a near-infrared spectroscopy (NIRS)-based algorithm for the personalized optimization
of cerebral oxygenation during cardiopulmonary bypass combined with a restrictive red cell transfusion threshold would
reduce perioperative injury to the brain, heart, and kidneys.
Methods. In a randomized controlled trial, participants in three UK centres were randomized with concealed allocation to a
NIRS (INVOS 5100; Medtronic Inc., Minneapolis, MN, USA)-based ‘patient-specific’ algorithm that included a restrictive red
cell transfusion threshold (haematocrit 18%) or to a ‘generic’ non-NIRS-based algorithm (standard care). The NIRS algorithm
aimed to maintain cerebral oxygenation at an absolute value of>50% or at>70% of baseline values. The primary outcome
for the trial was cognitive function measured up to 3 months postsurgery.
Results. The analysis population comprised eligible randomized patients who underwent valve or combined valve surgery
and coronary artery bypass grafts using cardiopulmonary bypass between December 2009 and January 2014 (n¼98 patient-
specific algorithm; n¼106 generic algorithm). There was no difference between the groups for the three core cognitive
domains (attention, verbal memory, and motor coordination) or for the non-core domains psychomotor speed and visuo-
spatial skills. The NIRS group had higher scores for verbal fluency; mean difference 3.73 (95% confidence interval 1.50, 5.96).
Red cell transfusions, biomarkers of brain, kidney, and myocardial injury, adverse events, and health-care costs were similar
between the groups.
Conclusions. These results do not support the use of NIRS-based algorithms for the personalized optimization of cerebral
oxygenation in adult cardiac surgery.
Clinical trial registration. http://www.controlled-trials.com, ISRCTN 23557269.
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Brain injury occurs in up to 40% of patients undergoing cardiac
surgery with cardiopulmonary bypass (CPB), where it contrib-
utes to morbidity, mortality, and the increased use of health-
care resources.1 This has been attributed in part to cerebral
hypoperfusion and hypoxia caused by non-physiological blood
flow during CPB, often in the presence of diseases that result in
abnormal autoregulation.2 3
Near-infrared spectroscopy (NIRS) is a non-invasive method
for the measurement of regional cerebral oxygenation and has
been shown to reflect cerebral mixed venous oxygen saturations
in cardiac surgery patients.4 It has been hypothesized that per-
sonalized goal-directed interventions directed towards increas-
ing regional brain oxygen saturation as measured by NIRS
during CPB might lead to reductions in brain injury4 or reduc-
tions in injury to other organs, including the heart and kidneys,
as a consequence of improved overall perfusion.5 It has also
been postulated that NIRS might be used to personalize transfu-
sion decisions, whereby red cell transfusions are used as one
component of a patient-specific algorithm designed to optimize
tissue oxygenation.6
To test these hypotheses and to address clinical uncertainty
regarding the benefits of NIRS-based algorithms7 reflected
by variability in their use,8 we performed a multicentre random-
ized controlled trial comparing a personalized goal-directed
NIRS-based algorithm that incorporated a restrictive red cell
transfusion threshold vs standard care in adult patients under-
going heart valve surgery with or without coronary artery
bypass grafting (CABG). The primary outcome for the trial was
cognitive function measured up to 3 months postsurgery.
Secondary outcomes included biomarkers of brain, kidney, and
myocardial injury, adverse events, and resource use.
Methods
Trial design and participants
The effects of patient-specific cerebral oxygenation monitoring
as part of an algorithm to reduce red cell transfusion in patients
having heart valve surgery (PASPORT) trial (registration ISRCTN
23557269 on February 27, 2009) was a parallel-group randomized
controlled trial conducted at three cardiac surgery centres in
the UK. Male and female adult patients undergoing open valve
or combined CABG and open valve surgery were eligible.
Exclusions, listed in Supplementary material Table S1, included
patients with pre-existing neurological disease or inflammatory
states. Participants provided written informed consent before
surgery but became eligible for randomization only if they
scored 24 on the Mini Mental State Examination (indicating no
cognitive impairment). The allocated intervention was applied
during CPB. Participants were followed up until discharge and
at 6 weeks and 3 months after randomization. The trial com-
plied with the Declaration of Helsinki. A UK National Health
Service (NHS) Research Ethics Committee (REC) approved the
study (09/H0102/13) on June 15, 2009. A detailed protocol has
been reported elsewhere.9 University Hospitals Bristol NHS
Trust was the trial sponsor. Changes to the trial after
commencement are described in the Supplementary material.
Randomization and blinding
Participants were randomly allocated to either the ‘generic’ or
‘patient-specific’ algorithms for optimizing tissue oxygenation
during CPB in a 1:1 ratio, stratified by centre and surgical proce-
dure (valve only or combined CABG and valve). Allocations,
blocked with varying block sizes, were generated by computer
and concealed using a secure password-protected internet-based
randomization system. Randomization occurred before surgery
after written informed consent was given and eligibility con-
firmed and as close to the planned surgery time as possible.
Patients and outcome assessors were blinded to group allocation.
Interventions
The trial compared two algorithms for optimizing tissue oxy-
genation during CPB, generic and patient-specific algorithms.
The interventions were defined as follows.
Generic algorithm (including a standard transfusion threshold)
This was a generic algorithm for optimizing tissue oxygenation
based on global measures of oxygen utilization and including a
predefined intraoperative haematocrit transfusion threshold of
23%.
Patient-specific algorithm (including a restrictive transfusion
threshold)
This was a patient-specific, goal-directed algorithm based on
the monitoring and optimization of regional cerebral oxygen
saturation measured using the INVOS 5000 NIRS device
(Somanetics, IN, USA), combined with a predefined ‘restrictive’
intraoperative haematocrit transfusion threshold of 18%.
Optimization of cerebral oxygenation used a modified Murkin
protocol10 (see Supplementary Table S2) that aimed to maintain
INVOS values at an absolute value of >50% or at >70% of base-
line values obtained in the anaesthetic room before induction
whilst breathing room air. If target cerebral oxygenation values
were not achieved by modifying aspects of pump flow, gas
exchange, or depth of anaesthesia as specified in the algorithm,
red cells could be transfused above the 18% haematocrit
threshold.
Details of perioperative care protocols, monitoring of proto-
col compliance, blinding of clinical staff, and other steps to miti-
gate bias are described in the Supplementary material.
Editor’s key points
• Personalized optimization of cerebral oxygen saturation
during cardiac surgery may reduce perioperative neuro-
nal injury.
• One manoeuvre for optimization is blood transfusion,
which poses its own risks.
• The authors developed an optimization protocol involv-
ing a transfusion threshold of haematocrit 18%.
• Cognitive outcomes were similar with this protocol
compared with a generic protocol (no near-infrared
spectroscopy optimization, haematocrit threshold 23%).
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Assessed for eligibility (n=764)
Patients excluded (n=556)
Ineligible (n=135)1:
Not approached (n=185):
Did not consent (n=227):
Excluded post consent (n=9):
MMSE score<24 (4), patient withdrawn post-consent but pre-randomisation (5).
Aged less than 16 (0),not valve/CABG and valve surgery (13), emergency surgery (3),
belief system preventing transfusion (0), elevated preoperative Hb requirement (38),
congenital or acquired RBC, platelet or clotting factor disorders (17), active inflammatory
state or sepsis (23), end stage renal failure or previous renal transpalnt (9), neurological
disorder (14), diagnosed psychiatric disorder or drug/alcohol addiction (5), previously
identified cognitive impairment (5), previous stroke/ intra-cerebral haemorrhage/ or
acquired brain injury (18), unable to complete neurocognitive assessments due to physical
disability (17), not able to give full informed consent (6), in other clinical trial (6).
Too unwell (3), clinician decision not to include patient (11), trial recruitment ended (4),
cancelled/transferred to theatre list of non-participating surgeon (23), other (5), insufficient time
(6), death (5), unknown (128).
Not enough time to consider study (19), too anxious (58), did not wish to take part (65), wants
standard procedure (20), did not want follow-up (15), other personal reasons (31), clinician
decision not to include patient (2), cancelled/transferred to theatre list of non-participating
surgeon (2), no reason given (15).
Randomised (n=208)
Allocated to generic algorithm (n=106) Allocated to patient-specific algorithm (n=102)
Withdrawals pre-surgery (n=3)Withdrawals pre-surgery (n=0)
Deaths pre-surgery (n=1)Deaths pre-surgery (n=0)
Deaths post-surgery (n=2)
Withdrawals post-surgery (n=2)Withdrawals post-surgery (n=5)
3 month follow-up data available (n=99)
Deaths post-surgery (n=1)
3 month follow-up data available (n=95)
Number of protocol deviations (19)
Personal reasons (1)
Did not want to participate in follow-up (1)
Personal reasons (2)
Did not want to participate in follow-up (3)
3 month questionnaire completed (88)
Neurocognitive data available (88)
Loss to follow-up (7)
3 month questionnaire completed (87)
Neurocognitive data available (87)
Loss to follow-up (12)
Number of protocol deviations (11)
Underwent surgery and included in analysis
population (n=98)
Underwent surgery and included in analysis
population (n=106)
Patient found to be ineligible after randomisation (1)
Patient decided not to go ahead with surgery (1)
Patient withdrawn due to emergency changes to theatre
list (1)
Fig 1 Flow of participants showing eligibility, recruitment, protocol deviations, withdrawals, and loss to follow-up in the PASPORT trial. MMSE, mini mental state
examination.
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Table 1 Participant characteristics and history. AF, atrial fibrillation; CCS, Canadian Cardiology Society; CVA, cerebrovascular accident;
IQR, interquartile range; NYHA, New York Heart Association; TIA, transient ischaemic attack; WTAR, Wechsler test of adult reading.
Missing data are as follows (generic algorithm, patient-specific algorithm): *one patient with missing data (0, 1); †one patient with missing
data (0, 1); ‡15 patients with missing data (9, 6); ¶52 patients with missing data (29, 23); §seven patients with missing data (2, 5)
Characteristic Randomized
to generic
algorithm (n¼106)
Randomized
to patient-specific
algorithm (n¼98)
Overall (n¼204)
n % n % n %
Demography
Sex (female) 32/106 30 32/98 33 64/204 31
Age (yr; mean, range) 70.0 29.5–88.7 65.9 18.5–86.6 68.0 18.5–88.7
BMI (kg m2; mean, SD) 27.5 4.6 27.8 5.6 27.6 5.1
NYHA class I 25/106 24 20/98 20 45/204 22
II 50/106 47 43/98 44 93/204 46
III 30/106 28 33/98 34 63/204 31
IV 1/106 1 2/98 2 3/204 1
Canadian Cardiology Society class Asymptomatic 49/106 46 53/98 54 102/204 50
I 18/106 17 21/98 21 39/204 19
II 21/106 20 15/98 15 36/204 18
III 15/106 14 9/98 9 24/204 12
IV 3/106 3 0/98 0 3/204 1
Angiogram/echocardiography results
Left ventricular function Good (>50%) 90/106 85 85/98 87 175/204 86
Moderate (30–50%) 16/106 15 13/98 13 29/204 14
>50% disease in left main stem 2/106 2 0/98 0 2/204 1
Coronary disease, number of vessels* None 71/106 67 70/97 72 141/203 6
Single 15/106 14 11/97 11 26/203 13
Double 11/106 10 9/97 9 20/203 10
Triple 9/106 8 4/97 4 13/203 6
Not investigated 0/106 0 3/97 3 3/203 1
Blood and urine results
Haemoglobin, gdL-1 (median, IQR) 14.2 (13.1, 15.5) 14.7 (13.3, 16.2) 14.4 (13.2, 16.2)
Haematocrit, % (median, IQR)† 40.0 (37.7, 42.0) 41.0 (38.0, 43.0) 41.0 (38.0, 43.0)
Platelets, 109L-1 (median, IQR) 220.0 (192.0, 258.0) 212.0 (186.0, 252.0) 217.0 (186.5, 255.5)
Creatinine, umolL-1 (median, IQR) 92.0 (77.0, 105.0) 87.5 (77.0, 104.0) 90.0 (77.0, 105.0)
Urine output during 3 h, ml (median, IQR)‡ 221.0 (144.0, 303.0) 250.0 (157.0, 370.5) 230.0 (152.0, 342.0)
Medical history
Diabetes No 100/106 94 86/98 88 186/204 91
Diet 2/106 2 4/98 4 6/204 3
Oral 4/106 4 6/98 6 10/204 5
Insulin 0/106 0 2/98 2 2/204 1
Pacemaker No 101/106 95 96/98 98 197/204 97
Temporary 1/106 1 0/98 0 1/204 1
Permanent 4/106 4 2/98 2 6/204 3
Heart rhythm Sinus 82/106 77 76/98 78 158/204 77
AF 21/106 20 19/98 19 40/204 20
Block 1/106 1 1/98 1 2/204 1
Paced 2/106 2 2/98 2 4/204 2
CVA or TIA 5/106 5 11/98 11 16/204 8
Smoking status No 56/106 53 45/98 46 101/204 50
Ex (>1 month) 43/106 41 47/98 48 90/204 44
Yes 7/106 7 6/98 6 13/204 6
Previous cardiac surgery 6/106 6 5/98 5 11/204 5
Myocardial infarction 12/106 11 8/98 8 20/204 10
Operative priority Elective 94/106 89 88/98 90 182/204 89
Urgent 12/106 11 10/98 10 22/204 11
Additive EuroScore (median, IQR) 5 (4, 7) 5.0 (3, 6) 5.0 (4, 7)
Medications
Heparin 2/106 2 0/98 0 2/204 1
Nitrates until theatre 1/106 1 0/98 0 1/204 1
Clexane within 12 h before surgery 1/106 1 1/98 1 2/204 1
Aspirin within 5 days before surgery 55/106 52 38/98 39 93/204 46
Clopidogrel within 5 days before surgery 3/106 3 3/98 3 6/204 3
Continued
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Outcomes
Timings of outcome assessment are listed in Supplemental
Table S3.
Primary outcome
The primary outcome for the trial was serial measures of cogni-
tive function on or between 4 and 7 days after surgery and again
at 3 months.11 12 Cognitive function was assessed by qualified
examiners, trained in the methods of neurocognitive assess-
ment used in the study and blinded to treatment allocation
before surgery. The following cognitive domains were tested.
• Attention: sustained and divided attention: trail-making test
parts A and B.
• Verbal memory: Rey Auditory Verbal Learning Test.
• Visuo-spatial: block design from the Wechsler Adult
Intelligence Scale.
• Psychomotor speed: digit symbol test from the Wechsler
Adult Intelligence Scale–Revised test.
• Executive function/verbal fluency: controlled oral word associ-
ation test.
• Motor coordination: grooved pegboard test, dominant and
non-dominant hand.
To help interpret the cognitive function data, the following
assessments were carried out for all participants.
• The Wechsler Test of Adult Reading (WTAR) provided a meas-
ure of intellectual ability, before surgery only.
• Documentation of medications known to interfere with neu-
ropsychological functions was carried out before and after
surgery.
• Assessment of the patient’s current mental health was done
using the General Health Questionnaire (GHQ-30) and
Hospital Anxiety and Depression Scale (HADS) before and
after surgery, to take into account the potential interaction
between postoperative cognition and mood.
Secondary outcomes
Secondary outcomes included biomarkers of the inflammatory
response [serum interleukin (IL)-6, IL-8], brain (serum S100), and
myocardial (serum troponin) injury. The effects of optimization
of cerebral oxygenation on kidney injury were assessed by
measurement of serum creatinine and calculated creatinine
clearance, and urine biomarkers of inflammation [neutrophil
gelatinase associated lipocalcin (NGAL), liver-fatty acid binding
protein (L-FAB)] and tubular epithelial injury [kidney injury mol-
ecule-1 and IL-18]. Clinical outcomes, resource use, and quality
of life were also recorded (Supplementary Table S4).
Sample size
We estimated that a sample size of 75 participants per group
would be sufficient to detect small-to-moderate standardized
differences between the two groups of 0.33 for the primary out-
come cognitive function (adjusting for baseline) and 0.4 for
inflammation and organ injury biomarkers (adjusting for base-
line and using four repeated measures) with 80% power and 5%
significance (two tailed). Correlations between repeated meas-
ures were assumed to be 0.7. For time to cardiac intensive care
unit or hospital discharge, the sample size allowed a hazard
ratio (HR) of 1.65 to be detected. During the trial, at the request
of the funder, the sample size was increased to 100 patients per
group because of a higher than expected dropout rate and a
lower than expected correlation between baseline and postin-
tervention cognitive function (no comparison between groups
was made when the sample size assumptions were reviewed).
Statistical analysis
The analysis population included all randomized participants,
excluding patients who died or withdrew after randomization
but before surgery. Outcomes are reported by intention to treat
and were directed by a prespecified statistical analysis plan
(see Supplementary material). Continuous variables are sum-
marized using the mean (SD), or the median and interquartile
range (IQR) if the distribution is skewed, and categorical data
are summarized as a number and percentage. Near-infrared
spectroscopy was summarized as an area under the curve
(AUC), as described in detail in the Supplementary material.
Primary and secondary outcomes were compared using linear
mixed model (continuous variables measured at multiple time
points), multiple (continuous variables summarized as a single
measurement), logistic (binary variables), or Cox proportional
hazards (time to event variables) regression, with the generic
algorithm as the reference group. All analyses were adjusted for
the stratification variables, centre, and surgical procedure.
Treatment effect estimates are reported with 95% confidence
intervals (CIs). Likelihood ratio tests were used to determine
statistical significance, and two tailed P-values <0.05 were con-
sidered statistically significant. Neurocognitive outcomes were
adjusted for the stratification variables and for reading ability at
Table 1 Continued
Characteristic Randomized
to generic
algorithm (n¼106)
Randomized
to patient-specific
algorithm (n¼98)
Overall (n¼204)
n % n % n %
b-Blockers 52/106 49 37/98 38 89/204 44
Psychotic medications
Hypnotics 4/106 4 1/98 1 5/204 2
Sedatives 4/106 4 1/98 1 5/204 2
Anxiolytics 4/106 4 0/98 0 4/204 2
Antidepressants 9/106 8 6/98 6 15/204 7
Any psychotic drug 17/106 16 8/98 8 25/204 12
Wechsler test of adult reading
WTAR standard score (median, IQR)§ 118.5 (108.0, 123.0) 117.0 (108.0, 122.0) 118.0 (108.0, 123.0)
388 | Rogers et al.
T
ab
le
2
C
og
n
it
iv
e
fu
n
ct
io
n
.C
I,
co
n
fi
d
en
ce
in
te
rv
al
;C
O
W
A
T
;C
on
tr
ol
le
d
O
ra
l
W
or
d
A
ss
oc
ia
ti
on
T
es
t;
G
M
R
,g
eo
m
et
ri
c
m
ea
n
ra
ti
o;
IQ
R
,i
n
te
rq
u
ar
ti
le
ra
n
ge
;R
A
V
LT
,R
ey
A
u
d
it
or
y
V
er
ba
l
Le
ar
n
in
g
te
st
;
W
A
IS
,W
ec
h
sl
er
A
d
u
lt
In
te
lli
ge
n
ce
Sc
al
e;
co
n
tr
ol
le
d
or
al
w
or
d
as
so
ci
at
io
n
te
st
;W
T
A
R
;W
ec
h
sl
er
T
es
t
of
A
d
u
lt
R
ea
d
in
g
M
D
,m
ea
n
d
if
fe
re
n
ce
;O
R
,o
d
d
s
ra
ti
o.
D
at
a
su
m
m
ar
iz
ed
ar
e
sc
al
ed
sc
or
es
,n
ot
ra
w
sc
or
es
.A
ll
tr
ea
tm
en
t
es
ti
m
at
es
ar
e
re
p
or
te
d
w
it
h
an
d
w
it
h
ou
t
ad
ju
st
m
en
t
fo
r
m
ed
ic
at
io
n
s,
H
A
D
s
an
d
G
H
Q
w
er
e
m
ea
su
re
d
af
te
r
su
rg
er
y.
R
aw
d
at
a
ar
e
ex
p
re
ss
ed
as
th
e
m
ea
n
(S
D
),
ex
ce
p
t
tr
ai
l-
m
ak
in
g
an
d
vi
su
al
m
ot
or
co
or
d
in
at
io
n
,w
h
ic
h
ar
e
ex
p
re
ss
ed
as
th
e
m
ed
ia
n
(I
Q
R
).
M
is
si
n
g
d
at
a
ar
e
as
fo
llo
w
s
(g
en
er
ic
al
go
ri
th
m
,p
at
ie
n
t-
sp
ec
ifi
c
al
go
ri
th
m
):
*s
ev
en
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(0
,7
);
†
35
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(2
0,
15
);
‡
31
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(2
0,
11
);
¶
19
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(9
,1
0)
;§
ei
gh
t
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(1
,7
);
k 4
1
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(2
5,
16
);
#
44
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(2
5,
19
);
**
34
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(2
1,
13
);
†
†
n
in
e
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(0
,9
);
‡
‡
42
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(2
3,
19
);
¶
¶
34
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(2
2,
12
);
§
§
18
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(6
,1
2)
;k
k 4
3
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(2
3,
20
);
##
35
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(2
2,
13
);
**
*1
6
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(5
,1
1)
;†
†
†
33
p
at
ie
n
ts
w
it
h
m
is
si
n
g
d
at
a
(2
0,
13
)
T
es
t
R
an
d
om
iz
ed
to
ge
n
er
ic
al
go
ri
th
m
(n
¼1
06
)
R
an
d
om
iz
ed
to
p
at
ie
n
t-
sp
ec
if
ic
al
go
ri
th
m
(n
¼9
8)
A
d
ju
st
ed
fo
r
b
as
el
in
e
co
va
ri
at
es
A
d
ju
st
ed
fo
r
ti
m
e-
sp
ec
if
ic
co
va
ri
at
es
M
ea
n
S
D
M
ea
n
S
D
Ef
fe
ct
(9
5%
C
I)
P-
va
lu
e
Ef
fe
ct
(9
5%
C
I)
P-
va
lu
e
1.
A
tt
en
ti
o
n
:t
ra
il
m
ak
in
g
(l
o
w
er
sc
o
re
is
be
tt
er
)
T
ra
il
B
co
m
p
le
ti
o
n
(s
;m
ed
ia
n
,I
Q
R
)
B
as
el
in
e*
98
.5
(7
4.
0,
14
0.
0)
86
.0
(6
2.
0,
11
1.
0)
5
d
ay
s
p
o
st
o
p
er
at
iv
e†
10
4.
5
(8
0.
0,
15
9.
0)
10
2.
0
(7
6.
0,
14
2.
0)
3
m
o
n
th
s
p
o
st
o
p
er
at
iv
e‡
87
.0
(6
4.
0,
12
6.
0)
76
.0
(6
0.
0,
98
.0
)
T
re
at
m
en
t
ti
m
e
in
te
ra
ct
io
n
0.
32
9
0.
16
6
O
ve
ra
ll
G
M
R
¼0
.9
9
(0
.9
3,
1.
07
)
0.
88
2
G
M
R
¼0
.9
9
(0
.9
1,
1.
06
)
0.
70
9
2.
V
er
ba
lm
em
o
ry
:R
A
V
LT
(h
ig
h
er
sc
o
re
is
be
tt
er
)
T
ri
al
V
Ih
av
in
g
ad
ju
st
ed
fo
r
ag
e
B
as
el
in
e¶
90
.8
17
.5
96
.2
17
.0
5
d
ay
s
p
o
st
o
p
er
at
iv
e#
80
.9
16
.0
81
.2
14
.9
3
m
o
n
th
s
p
o
st
o
p
er
at
iv
e*
*
92
.6
17
.1
93
.9
14
.8
T
re
at
m
en
t
ti
m
e
in
te
ra
ct
io
n
0.
53
4
0.
83
2
O
ve
ra
ll
M
D
¼
1
.7
5
0.
32
6
M
D
¼
0
.9
6
0.
61
4
(
5.
22
,1
.7
2)
(
4.
65
,2
.7
4)
3.
V
is
u
o
-s
p
at
ia
ls
ki
ll
s:
W
A
IS
II
I(
W
ec
h
sl
er
;h
ig
h
er
sc
o
re
is
be
tt
er
)
B
lo
ck
d
es
ig
n
h
av
in
g
ad
ju
st
ed
fo
r
ag
e
B
as
el
in
e§
11
.3
3.
6
11
.2
2.
6
5
d
ay
s
p
o
st
o
p
er
at
iv
e|
10
.9
3.
6
10
.5
2.
8
3
m
o
n
th
s
p
o
st
o
p
er
at
iv
e*
*
12
.0
3.
5
11
.6
3.
0
T
re
at
m
en
t
ti
m
e
in
te
ra
ct
io
n
0.
81
5
0.
96
1
O
ve
ra
ll
M
D
¼
0
.2
5
0.
36
4
M
D
¼
0
.0
01
0.
15
3
(
0.
77
,0
.2
8)
(
0.
57
,0
.5
7)
4.
Ps
yc
h
o
m
o
to
r
sp
ee
d
:W
A
IS
II
I(
W
ec
h
sl
er
;h
ig
h
er
sc
o
re
is
be
tt
er
)
D
ig
it
al
sy
m
bo
lc
o
d
in
g
h
av
in
g
ad
ju
st
ed
fo
r
ag
e
B
as
el
in
e†
†
9.
3
2.
6
9.
3
2.
6
5
d
ay
s
p
o
st
o
p
er
at
iv
e‡
‡
8.
1
2.
6
8.
4
2.
5
3
m
o
n
th
s
p
o
st
o
p
er
at
iv
e¶
¶
10
.4
2.
8
10
.4
2.
7
T
re
at
m
en
t
ti
m
e
in
te
ra
ct
io
n
0.
62
4
0.
96
1
O
ve
ra
ll
M
D
¼
0.
08
0.
73
3
M
D
¼
0.
33
0.
15
3
(
0.
37
,0
.5
2)
(
0.
12
,0
.7
9)
5.
Ex
ec
u
ti
ve
fu
n
ct
io
n
/v
er
ba
lfl
u
en
cy
:m
u
lt
il
in
gu
al
ap
h
as
ia
(C
O
W
A
T
;h
ig
h
er
sc
o
re
is
be
tt
er
)
W
o
rd
sc
o
re
h
av
in
g
ad
ju
st
ed
fo
r
ag
e
an
d
ye
ar
s
o
f
ed
u
ca
ti
o
n
B
as
el
in
e§
§
42
.2
12
.3
44
.2
11
.2
5
d
ay
s
p
o
st
o
p
er
at
iv
e|
|
37
.1
12
.9
42
.6
13
.7
3
m
o
n
th
s
p
o
st
o
p
er
at
iv
e#
#
41
.6
10
.5
45
.6
14
.1
T
re
at
m
en
t
ti
m
e
in
te
ra
ct
io
n
0.
42
8
0.
14
1
O
ve
ra
ll
M
D
¼
2.
72
0.
01
M
D
¼
3.
73
0.
00
11
(0
.6
4,
4.
80
)
(1
.5
0,
5.
96
)
C
on
ti
nu
ed
Cerebral oximetry in cardiac surgery | 389
recruitment, medication, and preoperative GHQ-30, HADS-
Anxiety and HADS-Depression scores. The overall treatment
effect for the primary outcome and for other continuous out-
comes measured at repeated time points was estimated across
the postsurgery time points, with adjustment for baseline differ-
ences. Where there was a significant timetreatment interac-
tion effect, estimates were calculated at each time point.
Significant differences in either the overall effect or for individ-
ual time points were considered evidence of a treatment effect
for that outcome. For the primary outcome, it was specified in
the statistical analysis plan that four out of six domains signifi-
cant at the 5% level would provide evidence to support the study
hypotheses. The trial was not powered to detect differences in
clinical outcomes, and their frequencies are tabulated
descriptively.
All analyses were performed in SAS version 9.3 (SAS
Institute Inc., Cary, NC, USA) and Stata version 13.0 (StataCorp
LP, College Station, TX, USA).
Results
Trial cohort and patient flows
The flow of patients through the trial is shown in Fig. 1. Two
hundred and eight patients were recruited and randomized
between December 2009 and January 2014. Four patients with-
drew before surgery. The analysis population therefore com-
prised 204 participants, 106 of whom were allocated to the
generic algorithm and 98 to the patient-specific NIRS algorithm.
Of the 204 randomized patients, 194 were eligible for follow-up
at 3 months, and 175 completed the 3 month questionnaire and
attended for the neurocognitive assessment, (n¼87 generic algo-
rithm, n¼88 patient-specific algorithm). Details of patient with-
drawals are listed in Supplementary Table S5. There were 30
protocol deviations; 11 in the generic algorithm group and 19 in
the patient-specific algorithm group (Supplementary Table S6).
Participant characteristics
Baseline characteristics were similar in the two groups (Table 1).
The mean age of participants was 68 (SD 11) yr, and 69% were
male. The median EuroScore was 5 in both groups. Overall, 157
(77%) participants were listed for valve surgery and 47 (23%) for
combined CABG and valve surgery. Bypass, cross-clamp, and
the overall duration of the surgery were similar in the two
groups (Supplementary Table S7). All participants were alive at
the end of the surgery.
Primary outcome
The results of the neurocognitive tests are shown in Table 2.
The scores for the cognitive domains attention, verbal memory,
visuo-spatial skills, psychomotor speed, and visual motor coor-
dination were similar between the groups. Effect estimates were
not significantly altered by adjustment for medications and
mental health during follow-up. For the executive function/ver-
bal fluency domain, mean scores were significantly better in the
patient-specific algorithm group [mean difference (MD)¼2.72
(95% CI 0.64, 4.80)], which increased when accounting for medi-
cation and mental health both at baseline and during follow-up
[MD¼ 3.73 (95% CI 1.50, 5.96)]. These differences did not meet
the prespecified definition of a reduction in cognitive
dysfunction.
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Secondary outcomes
Results for the secondary outcomes are shown in Figs 2 and 3 and
in Supplementary Table S8 and Figs S1 and S2. The groups were
similar with respect to the frequency of red cell transfusion
[RR¼0.88 (0.63–1.23), P¼0.47], NIRS area under curve, and mean
oxygen delivery and consumption during cardiopulmonary bypass
(CPB). Time to cardiac intensive care unit discharge [HR¼1.15 (95%
CI 0.87, 1.52), P¼0.32], time to hospital discharge [HR¼ 1.10 (95% CI
0.83, 1.45), P¼0.51], and quality of life measured using the EQ-5D
[odds ratio¼1.75 (95% CI 0.88, 3.50), P¼0.11; Supplementary Table
S9] were also similar. Serious expected adverse events and health-
care costs to 3 months were similar between the groups
(Supplementary Tables S10 and S11). Biomarker concentrations
were similar in the two groups for inflammation (IL-6, IL-8), brain
(serum S100), myocardial (serum troponin T), or kidney injury (Fig.
3 and Supplementary Fig. S2, Table S12 and Table S13).
Discussion
Main findings
The results of the PASPORT trial do not support the hypothesis
that a patient-specific NIRS-based algorithm for the management
of CPB results in reductions in neurocognitive dysfunction at up
to 3 months postsurgery. Use of NIRS did not result in periopera-
tive reductions in serum or urine biomarkers of brain, kidneys,
and myocardial injury, or in resource use.
Strengths and limitations
The PASPORT trial compared a widely used patient-specific
NIRS-based algorithm with standard care in three UK centres
where this technology is in common use for the optimization of
tissue oxygenation during CPB. It used detailed neurocognitive
assessments and complementary clinical measures and bio-
markers of injury and dysfunction in multiple organ systems.
The principal limitation of the trial was the limited blinding
of health-care personnel; only the researchers responsible for
the assessment of the neurocognitive and clinical outcomes
and the laboratory staff carrying out the biomarker assays were
blinded. We addressed this by documenting protocol compli-
ance. This demonstrated that the nature of protocol non-
adherence differed by group and also that the proportion of
patients with non-adherence to the Murkin protocol in the
intervention group was high (18%). This occurred despite all the
members of the clinical team at each of the recruiting centres
being familiar with the technology before conducting the trial.
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High levels of protocol non-adherence have been reported in a
similar trial.13 Although we cannot exclude the possibility that
this may have introduced bias, it is equally possible that we
have measured the normal application of this technology in a
complex and highly variable operating theatre environment.
Another limitation is that the trial recruited throughout a
prolonged period. It is possible that refinements in care may
have occurred during this period, although as these changes
will have been reflected in the trial cohort, this also increases
the relevance of the findings to contemporary practice.
Clinical relevance
We detected a significant difference in one neurocognitive domain,
executive function/verbal fluency, which favoured the patient-
specific NIRS group. However, this is not a core domain as defined
by the Consensus Statement for the Assessment of Neurocognitive
function in Cardiac surgery,11 and we did not conclude that this
was sufficient to demonstrate efficacy. We also consider it unlikely
that alternative definitions of neurocognitive dysfunction, such as
the composite Z score, would have altered our findings. This con-
clusion was supported by no significant difference between the
groups for the brain injury biomarker S100B. The NIRS levels were
similar in both groups, with relatively few patients experiencing
cerebral desaturation. We suggest that this may have contributed
to our clinical findings; low frequencies of cerebral desaturation
reduce the likelihood that NIRS-based algorithms will have clinical
utility. This is perhaps attributable to the supranormal levels of
oxygen delivery during CPB measured in the study; almost no
patient had values approaching critical oxygen delivery
(<500 ml min1). Important risk factors for neurocognitive dysfunc-
tion, such as increased age, diabetes, or poor left ventricular func-
tion, were also uncommon, and this may have influenced our
results. The potential for NIRS to contribute to cerebral protection
will also have been influenced by the presence or absence of other
factors that we did not quantify, such as cerebral emboli or pre-
existing white matter changes.14 Finally, our findings refuted the
hypothesis that a patient-specific algorithm that aims to optimize
cerebral NIRS values may have additional important benefits for
other organs, such as the heart and kidneys.5
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Conclusions
We did not demonstrate a clinical benefit for personalized, NIRS-
directed management of patients during CPB.4 These devices are
in widespread use.8 It is possible that our results are attributable
to chance, although we detected no difference between NIRS and
standard-care groups using multiple tests and assays that are
sensitive markers of injury to a range of organ systems.
Alternative hypotheses are that cerebral oxygen saturation meas-
ured by NIRS does not reflect cerebral oxygen utilization,15 or that
cerebral hypoxia is not the principal cause of post-CPB brain
injury.14 These findings support ongoing efforts to identify meas-
ures of cellular oxygen uptake16 that may have clinical utility.
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